Intellectual Property India Publishes Patent Application for 'RNAI Agents For Inhibiting Expression Of DM1 Protein Kinase (DMPK) Compositions Thereof, And Methods Of Use' Filed by Arrowhead Pharmaceuticals, Inc.

MUMBAI, India, June 13 -- Intellectual Property India has published a patent application (202517045970 A) filed by Arrowhead Pharmaceuticals, Inc., Pasadena, U.S.A., on May 13, for 'rnai agents for inhibiting expression of dm1 protein kinase (dmpk) compositions thereof, and methods of use.'

Inventor(s) include Van Dyke, Jonathan; Ai, Teng; Li, Xiaokai; Ding, Zhi-Ming; Pei, Tao; and Schienebeck, Casi.

The application for the patent was published on June 13, under issue no. 24/2025.

According to the abstract released by the Intellectual Property India: "Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of DM1 protein kinase (DMPK) gene. The DMPK RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a DMPK gene. Pharmaceutical compositions that include one or more DMPK RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described DMPK RNAi agents to skeletal muscle cells in vivo, provides for inhibition of DMPK gene expression and a reduction in DMPK protein levels, and more specifically a reduction in mutant DMPK-CUG protein levels, which can provide a therapeutic benefit to subjects, including human subjects, suffering from certain skeletal muscle-related diseases or disorders including myotonic dystrophy type 1."

The patent application was internationally filed on Oct. 18, 2023, under International application No.PCT/US2023/077179.

Disclaimer: Curated by HT Syndication.